Iole Mannella

Dr. Iole Mannella

Science and Drug Technology, University of Turin, Turin, Piedmont, Italy
+1
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2023 in Biomolecules
Verified
Journal Article
Open access
PDF file
Tomasz WróbelTomasz Wróbel
Tomasz Wróbel
KSKatyayani Sharma
Katyayani Sharma
IMIole Mannella
Iole Mannella
SOSimonetta Oliaro-Bosso
Simonetta Oliaro-Bosso
PNPatrycja Nieckarz
Patrycja Nieckarz
FBFredrik Björkling
Fredrik Björkling
This study reports on the synthesis and evaluation of novel compounds replacing the nitrogen-containing heterocyclic ring on the chemical backbone structure of cytochrome P450 17α-hydroxylase/12,20-lyase (CYP17A1) inhibitors with a phenyl bearing a sulfur-based substituent. Initial screening revealed compounds with marked inhibition of CYP17A1 activity. The selectivity of compounds was thereafter determined against cytochrome P450 21-hydroxylase, cytochrome P450 3A4, and cytochrome P450 oxidoreductase. Additionally, the compounds showed weak inhibitory activity against aldo-keto reductase 1C3 (AKR1C3). The compounds’ impact on steroid hormone levels was also assessed, with some notable modulatory effects observed. This work paves the way for developing more potent dual inhibitors specifically targeting CYP17A1 and AKR1C3.

12 October 2026 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
Giulia BononiGiulia Bononi
Giulia Bononi
GSGiulia Sibille
Giulia Sibille
Erika PlicantiErika Plicanti
Erika Plicanti
FTFabio Testori
Fabio Testori
GFGiusy L. Fratello
Giusy L. Fratello
Filippo MinutoloFilippo Minutolo
Filippo Minutolo
Endoplasmic reticulum (ER) oxidoreductases are promising targets for host-targeted antiviral agents (HTAs) because of their essential role in protein folding, including the maturation of viral proteins. Human protein disulfide isomerase family member A3 (PDIA3) is involved in the folding of N-glycosylated client proteins, including viral envelope proteins, making it an attractive but underexplored antiviral target. Here, we describe the discovery of a novel N-hydroxyindole-2-carboxamide class of PDIA3 inhibitors, exemplified by compound AV22 (1o), which effectively inhibits PDIA3 activity and exerts broad-spectrum antiviral activity against major human respiratory viruses. Mechanistic studies indicated that AV22 (1o) increased the release of non-infectious coronavirus particles and reduced disulfide bond formation in the coronavirus spike protein, indicating that its antiviral effect stems from interference with PDIA3 activity. This new class of HTAs provides promising leads for drug discovery targeting viral envelope protein maturation vulnerabilities and is suitable for developing new BSAs.